This roundtable series assesses the use of treatments targeting MET exon 14 skipping mutations in patients with non–small cell lung cancer discussed in virtual live events.
Part 2: Rare Mutations and Non-Clinical Barriers for Molecular Testing in NSCLC
December 16th 2021During a live virtual event, Ravi Salgia, MD, PhD, discussed issues with molecular testing and biopsies including delays and affordability, plus identifying and responding to rare mutations detected by molecular testing.